Industry Veteran Ankur Dhingra Appointed CFO of Illumina as Joydeep Goswami Departs

Illumina, a leading gene sequencing company, has announced the departure of Chief Financial Officer Joydeep Goswami. Stepping into Goswami’s shoes is Ankur Dhingra, the former executive of Summit Therapeutics (NASDAQ: SMMT). Goswami will continue to support the company in an advisory capacity until June 30.

Goswami, who brought over two decades of experience in the life sciences industry, had served as CFO since early 2023. Prior to his role at Summit, Dhingra served as CFO at medical test maker CareDx (NASDAQ: CDNA) and accumulated 18 years of experience at equipment maker Agilent Technologies (NYSE: A).

In February, the company projected annual core business revenue to remain nearly flat, reflecting subdued demand for genetic testing tools and diagnostics products extending into the current year. In December, Illumina announced plans to divest cancer diagnostic test maker Grail following a prolonged battle with U.S. and European antitrust enforcers, as well as opposition from activist investor Carl Icahn.

Despite the leadership transition, Illumina (NASDAQ: ILMN) reaffirmed its forecast for the first quarter and full-year 2024. This strategic decision reflects Illumina’s ongoing commitment to navigating regulatory challenges and optimizing its business portfolio for sustained growth.

Have you read?
Best Fashion Schools.
Best Universities.
Best Medical Schools.
Best International High Schools.
Countries: Most Female Billionaires.

This report/news/ranking/statistics has been prepared only for general guidance on matters of interest and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, CEOWORLD magazine does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

Email Address*

Name